Locations:
Search IconSearch
October 9, 2017/Cancer/News & Insight

At-Risk Breast Cancer Patients Benefit from Psychosocial Counseling

Carrying the gene confers the same fears as a diagnosis

fears_650x450

Increasing genetic testing is identifying patients at elevated risk for developing breast cancer. While most cancer centers prescribe mental health counseling to patients diagnosed with breast cancer, these services are generally not offered to at-risk patients. Cleveland Clinic has rectified this oversight by incorporating a psychologist into their multidisciplinary Breast Center team. The goal is to enhance satisfaction for patients with hereditary breast cancer risk (HBCR).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Many of these women have been traumatized by seeing a mother or sister who battled the disease, so it’s only natural they become anxious or depressed when they learn they may follow in those footsteps. It can be a very scary time,” says Kathleen Ashton, PhD, a board-certified clinical health psychologist.

As a member of the Breast Center team, Dr. Ashton sees at-risk patients on the same day that they see a genetic counselor, breast physician and breast surgeon. “Patients know we understand what they are facing,” she says.

Psychosocial and physical challenges

A pilot study conducted on patients referred to Dr. Ashton showed that in patients with HBCR, depression and anxiety levels were not as high as in patients with breast cancer, but they were still distressed.

“They share many traits, including fear of cancer, anxiety about their future and depression about the trauma they may soon face,” says Dr. Ashton.

Having to choose between a watch-and-wait philosophy, risk-reducing mastectomy or chemoprevention can cause a great deal of anxiety. “These are tough decisions to make that often require patients to have conversations with their family. These conversations can bring up traumatic memories of a parent with cancer, or trigger guilt about possibly passing the gene to their children,” says Dr. Ashton.

Patients who opt for risk-reducing surgery face additional challenges related to body image, sexual health, pain management and changes in social relationships.

“Adding a psychologist to the team can help with all these issues,” says Dr. Ashton.

Advertisement

Case for a psychological boost

The ability of psychosocial intervention to improve longevity and prevent recurrence in breast cancer patients is known. Less research has been done on patients with HBCR.

This prompted Dr. Ashton to conduct a small study in which 14 patients with BRCA mutations were treated with as few as three and as many as 15 cognitive behavioral therapy (CBT) sessions. The result was a statistically significant reduction in depression (PHQ-9) and anxiety (GAD-7).

“Learning to cope with the uncertainties of increased genetic risks is important for a positive outcome,” she explains.

Failure to cope can mean giving up. Patients with anxiety and depression are less likely to follow through with lifestyle changes that can reduce their risk, such as not smoking, not using alcohol and maintaining a healthy weight. They are also less likely to follow through when chemoprevention is prescribed.

But CBT can help patients approach an anxiety-inducing situation, rather than avoiding it.

“When depressed patients are having difficulty making a decision about risk-reduction surgery, CBT can help them move forward,” she says.

“We help patients understand that knowing they are at increased risk empowers them to decide what steps to take to control their risk. Ultimately, this impacts their health down the road.”

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad